An interview with ImageBiopsy Lab’s CEO Reinhard Krickl.
In an interview with SmartTRAK, Reinhard Krickl, CEO of Vienna-based ImageBiopsy, discusses the latest research and innovations in musculoskeletal (MSK) artificial intelligence (AI) radiology and orthopedic diagnostics at the 2026 American Academy of Orthopaedic Surgeons (AAOS) Annual Meeting.
Krickl highlights key capabilities of ImageBiopsy Lab’s surgical intelligence platform, which automates the extraction of vital data from X-rays, including bone mineral density, leg and hip alignments, and standardized Kellgren-Lawrence (KL) scores for osteoarthritis. He also discusses how the technology seamlessly integrates into existing PACS workflows, efficiency gains it provides to the ambulatory surgery center (ASC) setting and the company's strategy for securing US partnerships for its two FDA-approved modules.
Listen to the interview below (13:45 min) to learn more, including how standardized AI measurements are minimizing insurance pushback for prior authorizations and the company's long-term vision for a "prediction engine" that ties objective measurements to outcome data. A link to download a complete transcript of the interview is also provided below.
SmartTRAK: This is Elise Wolf with SmartTRAK. Today I've got Reinhard Krickl, who is the CEO of ImageBiopsy, and we're going to be learning about the company and the technology. So welcome.
Reinhard Krickl: Thanks for having me.
I would love for our subscribers to learn exactly about the technology and the company. Can you tell us a little bit about ImageBiopsy?
RK: That's a big question. So where to start? We actually are in the market for 10 years. We had our 10-year anniversary this year. We're really coming from radiology. By the way, we are based in Vienna, Austria, so a European company. We come from radiology and how we optimize in radiology, but focus on musculoskeletal (MSK), AI, radiology. So it's really kind of in that specific area. This makes it super relevant to actually focus on the vertical of orthopedic diagnostics. And that's where we really play.
Have you always been focused specifically on the musculoskeletal space?
RK: Absolutely. That's where we built our entire knowledge database. That's where we build our expertise. And that's the vertical we want to play in.
AI is, and has been such a buzzword, and it feels like in the last 18-24 months, the technology is really gaining traction. Can you talk a little bit about what your vision was initially, and then where you are now?
RK: I think one of the most important things is that AI is...
Want to learn more about the latest research and innovations in musculoskeletal (MSK) artificial intelligence (AI) radiology? Click the button below to download the full transcript of Elise Wolf’s AAOS 2026 interview with ImageBiopsy CEO Reinhard Krickl.
SmartTRAK is the Medtech industry’s only global Insights-as-a-Service solution for the Orthopedics, Wound Care, Regenerative Medicine and Neuro Therapy markets. SmartTRAK’s proprietary methodology turns disparate data from hundreds of sources into powerful insights customers can rely on as the trusted source for strategic decision-making. The SmartTRAK enterprise platform includes rich daily updates, comprehensive market coverage and simple-to-use tools and dashboards for market, product and financial analysis. Customers leveraging the SmartTRAK platform also have direct access to market experts for inquiries and advisory services. If you would like a demo of what SmartTRAK has to offer and see how we can help increase proficiency, improve productivity and reduce costs for your company, just click here.
